ebola
outbreak
largest
record
took
us
larg
unprepar
avail
vaccin
specif
treatment
context
world
health
organ
declar
humanitarian
use
experiment
therapi
ebola
viru
ebov
ethic
particular
experiment
treatment
consist
cocktail
three
monoclon
antibodi
mab
produc
tobacco
plant
specif
direct
ebola
viru
glycoprotein
gp
test
human
appar
good
result
sever
mab
high
affin
gp
describ
review
discuss
current
knowledg
topic
particular
emphasi
devot
mab
assay
anim
model
human
possibl
therapi
ebola
engin
aspect
challeng
product
antiebola
mab
also
briefli
discuss
current
platform
design
product
fulllength
mab
cumbersom
costli
recent
ebola
outbreak
began
west
africa
decemb
made
evid
unprepar
effect
control
diseas
enserink
brad
juli
document
case
infect
includ
death
six
differ
african
countri
guinea
liberia
nigeria
mali
sierra
leon
seneg
addit
eight
case
outsid
west
africa
five
usa
one
spain
one
unit
kingdom
one
itali
clinic
manifest
evd
review
elsewher
feldmann
geisbert
bah
et
al
viru
reproduc
spread
bodi
interfer
blood
clot
disrupt
electrolyt
balanc
base
current
treatment
evd
consist
support
care
patient
frequent
dehydr
need
intraven
oral
fluid
solut
contain
electrolyt
bah
et
al
lyon
et
al
zhong
et
al
maintain
oxygen
level
modul
coagul
feldmann
geisbert
geisbert
et
al
import
part
treatment
scheme
ebola
patient
bah
et
al
lyon
et
al
zhong
et
al
intervent
help
sustain
patient
allow
recov
adequ
level
support
care
might
improv
surviv
significantli
bah
et
al
lyon
et
al
even
condit
patient
progress
toward
multiorgan
failur
shock
death
base
report
overal
fatal
rate
current
ebola
outbreak
span
goe
strong
function
qualiti
support
care
receiv
lyon
et
al
state
commerci
vaccin
specif
therapi
current
avail
combat
ebola
sever
experiment
vaccin
drug
test
anim
model
promis
result
current
clinic
trial
kuehn
comprehens
analysi
state
art
vaccin
develop
strategi
ebov
found
elsewher
regard
therapeut
approach
ebov
main
strategi
test
anim
model
includ
use
phosphorodiamid
morpholino
oligom
pmo
amongst
experiment
therapi
propos
test
evd
passiv
immun
use
fulllength
mab
arguabl
promis
strategi
context
largest
ebola
outbreak
ever
regist
declar
use
experiment
drug
humanitarian
treatment
ebola
patient
ethic
experiment
treatment
mapp
biopharmaceut
inc
san
diego
ca
consist
cocktail
three
mab
produc
tobacco
leav
administ
sever
patient
hampton
goodman
humanitarian
except
evolut
two
three
patient
first
treat
two
american
health
worker
infect
liberia
treat
emori
hospit
atlanta
usa
recent
document
lyon
et
al
patient
improv
condit
shortli
receiv
first
dose
sinc
improv
occur
context
aggress
rehydr
electrolyt
balanc
care
measur
signific
effect
mab
cocktail
conclus
establish
applic
lyon
et
al
target
differ
epitop
ebola
viru
gp
current
outbreak
mab
cocktail
use
human
predecessor
test
murin
nonhuman
primat
model
oling
et
al
pettitt
et
al
qiu
et
al
interf
viral
attach
viral
entri
mammalian
cell
common
therapeut
approach
fight
envelop
virus
wisskirchen
et
al
therapeut
use
fulllength
antibodi
viral
infect
propos
obstruct
viral
entri
context
west
nile
herp
simplex
highland
et
al
studi
refer
antibodi
specif
bind
differ
epitop
gp
inde
mab
propos
use
antiebola
therapeut
viru
transmembran
gp
target
logic
transmembran
gp
key
initi
viru
attach
fusion
host
membran
nanbo
et
al
sakurai
et
al
see
figur
gp
surfac
capsid
protein
ie
transmembran
protein
spike
protrus
surfac
viru
see
figur
play
key
role
mani
import
ebov
function
includ
interact
host
cell
receptor
activ
viral
attach
andor
entri
gp
also
antigen
ebov
protein
instanc
serum
evd
survivor
collect
day
end
symptom
react
mainli
gp
peptid
becquart
et
al
current
gp
believ
requir
suffici
vivo
virul
groseth
et
al
provid
brief
summari
current
knowledg
structur
function
gp
particularli
relev
design
andor
efficaci
antigp
mab
therapi
sever
glycoprotein
form
gp
origin
gpencod
rna
sequenc
transmembran
form
gp
normal
refer
literatur
simpli
gp
secret
gp
sgp
smaller
version
sgp
name
small
sgp
ssgp
among
relev
lee
et
al
mehedi
et
al
figur
sgp
may
act
distractor
host
immun
system
de
la
vega
et
al
misasi
sullivan
mohan
et
al
highli
present
dimer
solut
serum
infect
patient
serv
bind
target
antigp
antibodi
produc
host
perhap
effect
diminish
number
antibodi
avail
viru
neutral
mohan
et
al
ramanan
et
al
transmembran
gp
ebov
protein
contain
high
number
nlink
olink
carbohydr
takada
et
al
matur
transmembran
gp
trimer
subunit
link
disulfid
bond
subunit
gener
proteolyt
cleavag
precursor
polypeptid
viru
assembl
membranedist
subunit
respons
viral
adhes
host
cell
regul
transmembran
subunit
particip
membran
fusion
white
schornberg
malashkevich
et
al
accur
inform
threedimension
structur
transmembran
gp
deriv
small
number
wellexecut
studi
lee
et
al
beniac
et
al
tran
et
al
structur
trimer
gp
ectodomain
figur
graphic
refer
chalic
consist
base
head
glycan
cap
lee
et
al
lee
et
al
base
project
transmembran
anchor
residu
gp
attach
viral
membran
malashkevich
et
al
structur
compos
protein
beniac
et
al
cover
lipid
bilay
origin
cell
host
upon
viral
bud
figur
glycan
cap
highli
glycosyl
region
within
contain
nlink
glycosyl
site
hyperglycosyl
charact
major
role
steric
immun
shieldingmask
eleg
set
sitedirect
mutagenesi
experi
lennemann
et
al
nlink
glycan
site
ebov
total
systemat
disrupt
better
understand
role
gp
function
loss
ebov
glycosyl
site
enhanc
pseudovirion
infect
vero
cell
result
also
indic
glycan
capmld
domain
mask
rbd
residu
requir
bind
ebov
entri
murin
macrophag
still
occur
independ
presenc
nglycan
suggest
nglycan
interact
requir
entri
least
cell
type
one
main
primari
ebov
target
also
remov
nonmld
nglycan
enhanc
antibodi
sensit
togeth
observ
suggest
nlink
glycan
ebov
core
protect
gp
antibodi
neutral
despit
effect
glycan
might
diminish
infect
effici
lennemann
et
al
role
glycan
cap
protector
receptorbind
domain
well
understood
howev
still
incomplet
knowledg
mechan
ebovhost
cell
fusion
subsequ
viral
entri
good
summari
current
knowledg
particular
area
recent
provid
gehr
experiment
evid
indic
cell
bind
trigger
chain
biochem
signal
lead
viral
entri
cell
macropinocytosi
nanbo
et
al
figur
endosom
proteolysi
gp
appar
mediat
low
phdepend
cystein
proteas
ie
cathepsin
b
l
remov
glycan
cap
expos
receptor
bind
domain
facilit
membran
fusion
viru
cell
endosom
proteolit
cleavag
glycan
cap
appear
requir
infect
misasi
et
demonstr
endosom
calcium
channel
call
twopor
channel
tpc
requir
ebov
entri
host
cell
bind
mab
gp
interfer
least
partial
viru
first
interact
host
cell
later
entri
infect
endosom
figur
precis
main
rational
use
mab
cocktail
instead
singl
mab
extend
breath
protect
bind
multipl
gp
region
effici
mitig
immun
escap
et
polyclon
antibodi
directli
recov
concentr
nonhuman
primat
nhp
surviv
ebov
infect
treat
nhp
lethal
challeng
ebov
polyclon
mix
provid
full
protect
anim
even
first
dose
administ
hour
ebov
challeng
current
outbreak
treatment
plasma
whole
blood
convalesc
patient
use
particular
massiv
implement
evd
treatment
use
convalesc
plasma
evalu
costeffect
countermeasur
ebov
gutfraind
meyer
kreil
first
success
case
protect
use
antigp
ebov
mab
cocktail
nonhuman
primat
lethal
challeng
ebov
report
oling
et
al
current
mabbas
therapi
proven
effici
strategi
revers
progress
lethal
ebov
challeng
nonhuman
primat
limit
promis
therapeut
evid
human
nearli
antigp
fulllength
mab
describ
recent
literatur
includ
least
four
differ
group
led
research
effort
develop
antiebola
therapeut
candid
see
tabl
mab
target
differ
epitop
linear
conform
gp
zair
ebov
protein
antibodi
crossreact
report
among
np
ebola
virus
antibodi
bind
gp
specif
kamata
et
al
howev
mab
tabl
also
recogn
gp
ebov
speci
exampl
mab
bind
epitop
highli
conserv
among
zair
sudan
ivori
coast
ebov
remark
recent
paper
flyak
et
al
report
sever
antigp
marbug
mab
also
bind
ebov
gp
figur
illustr
graphic
way
gp
region
target
mab
inform
relev
perspect
drug
design
drug
prescriptionperson
note
even
among
zair
ebov
strain
mab
may
recogn
epitop
equal
affin
differ
genet
variant
instanc
gp
region
aa
comprehend
genet
variat
zair
ebov
strain
therefor
therapeut
mab
would
target
epitop
within
region
might
bind
gp
differ
patient
geograph
locat
extrem
case
zair
ebov
mab
bind
epitop
locat
region
rel
low
conserv
hand
mab
tabl
highli
conserv
zair
ebov
figur
next
review
bodi
publish
research
document
potenti
therapeut
use
promis
antigp
ebov
mab
among
refer
tabl
particular
refer
experiment
evid
use
one
mab
name
lee
et
al
see
figur
six
mab
use
three
differ
cocktail
name
zmab
proven
protect
ebov
lethal
challeng
nonhuman
primat
qiu
et
tabl
mab
one
first
best
describ
neutral
ebov
mab
lee
et
al
analyz
structur
gp
bound
antibodi
origin
isol
kikwit
outbreak
human
survivor
figur
author
use
xray
crystallographi
resolv
interact
site
structur
detail
residu
surfac
gp
variabl
region
tabl
antibodi
recogn
rel
small
gp
residu
glycanunprotect
region
protein
neighbor
viral
membran
surfac
see
figur
b
e
epitop
contain
residu
figur
c
lee
et
al
lee
et
al
mab
prove
protect
lethal
ebov
challeng
guinea
pig
administ
immedi
infect
parren
et
al
experi
medium
high
level
viremia
survivor
anim
suggest
mechan
ie
tag
activ
elimin
infect
cell
besid
viru
neutral
respons
protect
interestingli
unabl
provid
protect
lethal
challeng
nonhuman
primat
oswald
et
al
even
dose
mgkg
shown
suffici
diseasemab
case
author
test
three
mab
predecessor
found
protect
lethal
ebola
challeng
rhesu
macaqu
administ
h
postinfect
tobacco
version
approxim
three
time
effect
cho
analog
murin
model
presum
due
nonmammalian
lack
core
fucos
glycosyl
pattern
pilot
studi
primat
model
three
mgkg
dose
tobaccoderiv
mab
protect
three
three
ebolainfect
macaqu
administ
within
first
h
viru
exposur
refin
experi
pettitt
et
al
group
macaqu
receiv
lethal
ebola
viru
challeng
treat
three
dose
mgkg
sever
hour
present
ebola
symptom
four
five
day
exposur
three
seven
macaqu
surviv
challeng
combin
therapi
zmabanoth
cocktail
compos
murin
mab
adifn
adenovirusvector
protect
rhesu
macaqu
administ
three
day
posit
ebola
diagnosi
qiu
et
al
recent
report
differ
mab
contain
zmab
test
lethal
challeng
ebov
experi
guinea
pig
nonhuman
primat
first
round
experi
author
test
singl
dose
individu
mab
combin
experi
individu
mab
abl
provid
protect
level
surviv
prove
effect
mab
singledos
experi
contrast
mab
cocktail
provid
protect
level
guinea
pig
second
round
lethal
challeng
experi
time
use
scheme
three
dose
mab
cocktail
mab
combin
provid
full
protect
promisingli
administr
mab
therapi
start
three
four
five
day
lethal
challeng
viremia
measur
rtpcr
high
mab
cocktail
render
best
result
combin
mousehuman
chimer
mab
zmab
murin
mab
zmab
mab
formul
see
figur
select
mapp
biopharmaceut
inc
test
brand
name
produc
mapp
biopharmaceut
inc
recent
approv
humanitarian
use
ebola
patient
clearli
mab
therapi
use
cocktail
proven
help
emerg
resourc
treat
ebola
patient
although
evid
exist
point
insuffici
anticip
high
profici
largescal
clinic
intervent
limit
avail
robust
reliabl
vitro
assaysplatform
capabl
predict
therapeut
valu
antiebov
mab
anim
model
import
challeng
antiebov
mab
research
develop
abil
monoclon
antibodi
neutral
ebov
cell
cultur
assay
necessarili
mean
mab
protect
anim
model
moreov
characterist
condit
make
antibodi
protect
ebov
anim
model
andor
human
fulli
understood
furthermor
protect
abil
specif
mab
one
anim
model
necessarili
impli
provid
protect
anoth
anim
model
nacayama
saijo
comprehens
review
differ
anim
model
use
studi
ebov
infect
mainli
rodent
nonhuman
primat
nhp
summar
strength
weak
nhp
particularli
rhesu
cynomolgu
macaqu
better
mimic
ebov
infect
human
close
reproduc
symptom
diseas
rodent
howev
use
nhp
present
research
signific
practic
ethic
hurdl
nacayama
saijo
geisbert
et
al
use
rodent
differ
rodent
model
develop
ebov
research
includ
knockout
variant
brannan
et
al
practic
use
rodent
laboratori
possibl
use
genet
modifi
anim
made
attract
model
studi
protect
effect
antiebov
therapi
vaccin
howev
ebov
adapt
caus
lethal
infect
rodent
repres
highli
restrict
situat
given
high
risk
present
handl
pathogen
ebov
moreov
wide
use
rodent
mice
guinea
pig
exhibit
distinct
symptom
ebov
primat
fever
rash
suggest
dissimilar
antiebov
immun
respons
rodent
primat
gener
antiebov
protect
rodent
conclus
indic
protect
human
probabl
best
exampl
case
mab
neutral
protect
rodent
nhp
particular
case
antiebov
mab
therapi
nhp
studi
appear
mandatori
step
predict
efficaci
human
howev
clear
correl
establish
therapeut
effect
nhp
human
due
limit
amount
clinic
data
human
antiebola
mabbas
therapi
incomplet
knowledg
mechan
action
previous
state
use
antigp
mab
cocktail
mainli
intend
interfer
function
ebovgp
bind
gp
differ
epitop
figur
brief
antiebov
mab
believ
directli
interfer
ebov
infect
four
differ
stage
host
cell
attach
b
endosom
proteas
cleavag
c
endosom
receptor
bind
virushost
cell
membran
fusion
figur
howev
knowledg
mechan
antiebov
mab
therapi
may
work
remain
incomplet
summari
current
knowledg
effect
mechan
action
mabbas
therapi
follow
experi
administ
nonhuman
primat
oling
et
al
pettitt
et
al
number
viral
gene
copi
surviv
monkey
measur
rtpcr
significantli
reduc
two
four
order
magnitud
first
two
dosag
suggest
therapi
effect
interfer
viremia
progress
addit
experi
titer
specif
antigp
igg
much
higher
survivor
plausibl
interpret
observ
mab
therapi
retard
infect
progress
long
enough
allow
host
immun
system
mount
suffici
effici
immun
respons
high
antigp
titer
appear
correl
ebov
infect
surviv
hand
consider
bodi
experiment
evid
indic
ebov
multipl
way
evad
interfer
host
immun
respons
interfer
strategi
mediat
transmembran
sgp
see
figur
wong
et
al
evalu
correl
immun
respons
surviv
rodent
lethal
challeng
vaccin
ebov
use
knockout
mice
impair
abil
gener
normal
b
andor
cell
respons
particular
vaccin
anim
impair
b
cell
respons
unabl
surviv
challeng
wild
type
counterpart
impair
anim
capabl
mount
certain
level
protect
result
suggest
protect
mice
mainli
mediat
b
cell
cell
high
correl
gpspecif
total
immunoglobulin
g
igg
level
surviv
found
vaccin
guinea
pig
nonhuman
primat
although
mechan
protect
vaccin
necessarili
infect
intervent
result
clearli
suggest
gp
play
relev
role
infect
propag
tabl
bind
gp
inform
might
use
design
mab
cocktail
therapi
note
mab
may
inhibit
differ
gp
role
bind
differ
epitop
figur
differ
gp
form
figur
g
sinc
epitop
access
mab
bind
gp
form
ie
mdl
transmembran
gp
protect
epitop
locat
nearbi
receptor
bind
domain
mab
bind
cleav
form
gp
state
antiebov
directli
interfer
progress
ebov
infect
differ
stage
host
cell
attach
mab
bind
affin
expos
epitop
transmembran
gp
figur
might
steric
imped
gp
bind
differ
cell
attach
factor
figur
mab
might
obstruct
enzymat
cleavag
conduct
proteas
endosom
figur
block
bind
cleav
form
gp
figur
cell
receptor
also
present
endosom
ie
henc
obstruct
activ
process
endosom
viruscel
fusion
see
white
schornberg
moreov
gp
also
undergo
endosom
cleavag
releas
trigger
complex
structur
rearrang
mediat
viruscel
membran
fusion
experiment
evid
suggest
mab
may
bind
simultan
region
obstruct
cleavag
rearrang
dia
et
al
recognit
differ
epitop
differ
stage
viral
infect
result
differ
observ
bind
affin
neutral
kinet
mab
shedlock
et
al
publish
comprehens
compar
studi
antigp
bind
affin
publish
far
see
figur
experi
design
measur
extent
infect
inhibit
use
five
differ
antigp
ebov
mab
author
expos
endotheli
cell
cultur
gppseudovir
particl
presenc
differ
concentr
mab
observ
inhibit
profil
differ
significantli
mab
mab
figur
drastic
infect
inhibit
obtain
use
close
follow
interestingli
case
result
suggest
maximum
inhibit
vitro
concentr
also
capabl
interf
infect
effici
model
much
higher
concentr
author
also
report
discuss
import
differ
bindingneutr
behavior
among
mab
bind
conform
epitop
contain
residu
howev
mechan
two
mab
inhibit
infect
could
differ
bind
trimer
gp
cleav
gp
controversi
remain
abil
bind
effect
cleav
shedlock
et
al
found
unabl
bind
gppseudovir
particl
actual
ebov
particl
isol
gp
molecul
treat
cathepsin
cleav
gp
report
demonstr
capabl
bind
purifi
cleav
gp
trimmer
hood
et
al
believ
bind
cleav
gp
restrain
conform
chang
requir
membran
fusion
dia
et
al
hand
recogn
epitop
gp
sgp
exhibit
greater
affin
sgp
transmembran
gp
probabl
due
increas
exposur
correspond
epitop
sgp
compar
gp
shedlock
et
al
murin
et
al
mab
recogn
linear
epitop
mld
unabl
interfer
infect
exhibit
affin
sgp
cleav
gp
gp
lose
mld
cleavag
shedlock
et
al
mab
also
target
mld
proven
protect
anim
model
particular
mab
probabl
equival
mab
refer
wilson
et
al
recogn
linear
nonglycosyl
epitop
mld
olal
et
al
precis
bind
site
two
mab
describ
detail
olal
et
al
recent
paper
murin
et
al
use
singl
particl
em
attempt
precis
identifi
bind
site
conform
antibodi
contain
zmab
cocktail
result
confirm
mab
constitu
bind
perpendicularli
expect
plane
membran
straight
onto
surfac
gp
region
glycan
cap
similarli
bind
glycan
cap
gp
partial
interf
author
also
show
mab
bind
mld
without
interf
mab
simultan
target
epitop
base
gp
epitop
overlap
extens
antibodi
differ
mainli
angl
approach
overlap
bind
site
like
simultan
bind
appear
bind
almost
exclus
mab
bind
slightli
lower
gp
encompass
base
similar
footprint
identifi
murin
et
al
well
footprint
determin
crystallograph
lee
et
al
includ
residu
point
mutat
abolish
bind
qiu
et
al
also
abolish
bind
murin
et
al
experiment
evid
suggest
glycosyl
differ
glycosyl
pattern
might
play
role
design
select
recombin
platform
product
antiebola
mab
threefold
differ
effect
formul
produc
tobacco
versu
express
cho
cell
line
suggest
differ
glycosyl
eg
absenc
fucos
attach
constant
region
portion
fulllength
antibodi
might
play
role
observ
therapeut
effect
absenc
core
fucos
fulllength
antibodi
increas
bind
mab
wellcharacter
cell
receptor
macrophag
guilliam
et
al
result
signific
enhanc
antibodydepend
cellmedi
cytotox
adcc
activ
compar
fucosyl
antibodi
produc
cho
cell
line
figur
conclus
observ
suggest
fulllength
antibodi
without
fucos
better
infectedcel
marker
fulllength
antibodi
fucos
indic
rel
import
adcc
activ
versu
simpl
viru
entri
interfer
hand
choderiv
formul
still
protect
nonhuman
primat
lethal
ebola
challeng
administ
higher
dose
suggest
adcc
stimul
absolut
requir
protect
oling
et
al
summari
two
main
mechan
appear
involv
therapeut
effect
antigp
mab
interfer
viral
function
name
attach
cleavag
entri
tag
immun
system
attack
know
rel
import
two
effect
peerreview
publish
research
yet
avail
particular
topic
antiebola
mab
therapi
appear
promis
resourc
combat
evd
one
sever
problem
remain
product
mab
complex
process
biopharmaceut
engin
perspect
current
avail
product
platform
suffici
effect
respond
quickli
emerg
current
ebola
outbreak
unpreced
term
number
peopl
infect
rapid
progress
broad
geograph
extent
hand
mab
dose
requir
patient
might
high
base
dose
proven
effect
preclin
studi
nonhuman
primat
ie
mg
kg
mab
oling
et
al
simpl
extrapol
human
averag
weight
kg
suggest
approxim
g
mab
would
requir
treat
ebola
patient
scenario
peopl
requir
treatment
per
month
happen
octob
g
requir
monthli
far
produc
tobacco
plant
highyield
transient
express
strategi
tobacco
leav
plant
six
eight
week
old
cotransfect
construct
contain
genet
inform
synchron
product
heavi
light
chain
antibodi
giritch
et
al
castilho
et
al
strategi
labor
intens
definit
use
produc
suffici
amount
mab
rapidli
pilot
studi
howev
produc
kg
mab
approxim
ton
leav
would
transfect
separ
process
requir
recov
mab
tobacco
biomass
straightforward
fulton
et
al
yet
optim
scaleup
suitabl
handl
ton
biomass
stabl
express
matur
tobacco
plant
anoth
option
less
labor
intens
scalabl
develop
tobacco
plant
stabl
express
requir
invest
sever
month
hood
et
al
et
al
practic
option
express
mammalian
cell
therapeut
mab
commerci
produc
recombin
technolog
suspend
mammalian
cell
cultur
stir
tank
li
et
al
optim
commerci
process
least
g
mab
l
purif
produc
two
week
fedbatch
cultur
standard
stirredtank
bioreactor
use
cho
cell
warhors
product
glycosyl
biopharmaceut
li
et
al
et
al
produc
kg
mab
would
requir
process
l
cultur
media
monthli
proposit
feasibl
high
complex
cost
mammalian
cell
cultur
seriou
drawback
technolog
altern
oper
cost
singl
cho
cell
cultur
approxim
us
importantli
construct
isol
stabl
highproduc
cho
cell
clone
would
demand
less
day
develop
work
optim
scaleup
cho
cell
cultur
bioreactor
would
demand
three
four
addit
month
li
et
al
even
assum
optim
process
place
produc
mab
cocktail
cho
cell
technolog
path
could
still
compromis
due
rel
low
product
product
platform
high
dose
requir
treat
ebola
patient
illustr
treat
patient
approxim
total
number
confirm
case
report
march
st
kg
mab
would
requir
approxim
yearli
worldwid
instal
capac
mab
product
ecker
et
al
use
properli
engin
mab
fragment
instead
fulllength
mab
therapeut
altern
yet
investig
ebola
product
mab
fragment
provid
sever
import
technolog
possibl
even
therapeut
advantag
mab
fragment
suggest
interfer
viral
infect
easili
massiv
produc
simpler
bioreactor
cost
requir
produc
fulllength
mab
cho
cell
figur
mabbas
antiebov
therapi
must
investig
assur
safeti
effect
largescal
clinic
intervent
mabbas
cocktail
yet
subject
formal
clinic
trial
yet
cocktail
might
enter
clinic
trial
usa
year
even
preclin
data
nonhuman
primat
still
limit
hand
mab
test
nhp
three
mab
cocktail
test
human
ideal
set
mab
test
anim
model
expand
research
need
fulli
understand
mechan
differ
mab
mab
cocktail
interfer
progress
evd
nhp
wide
avail
anim
model
ration
extrapol
preclin
data
human
accomplish
first
set
clinic
data
becom
avail
recent
viral
hemorrhag
fever
immunotherapeut
consortium
vic
worldwid
research
consortium
head
erika
saphir
known
vic
initi
massiv
screen
antigp
antibodi
laboratori
across
globe
order
identifi
best
antiebov
therapeut
candid
preclin
test
deeper
understand
mechan
differ
mab
interfer
ebov
infect
provid
element
ration
design
antiebov
mab
cocktail
relev
detail
process
ebov
entri
infect
propag
still
unknown
exampl
import
mld
cleavag
expos
rbd
interact
viru
inner
outer
cell
surfac
need
clarifi
addit
rel
import
mab
interfer
relev
gp
function
versu
mab
tag
induc
adcc
activ
yet
investig
final
technolog
issu
resolv
make
feasibl
massiv
product
antiebov
mab
current
avail
platform
yet
adapt
produc
suffici
mab
quantiti
fast
enough
respond
epidem
outbreak
known
antigp
mab
interfer
key
gp
function
differ
stage
progress
ebov
infect
upon
interact
host
cell
attach
factor
precis
receptor
complex
seri
biochem
signal
trigger
eventu
lead
ebov
entri
macropinocytosi
endosom
format
sever
mab
known
interfer
viruscel
attach
black
mab
b
transmembran
gp
cleav
proteas
dark
green
symbol
within
endosom
enzymat
cleavag
remov
mld
region
indic
lighter
shade
yellow
glycan
cap
expos
rbd
sever
mab
bind
cleav
form
gp
interfer
gp
bind
cell
receptor
pink
antibodi
c
enabl
interact
viral
gp
cell
receptor
blue
oval
rbd
interact
cleav
gp
cell
receptor
vgr
trigger
viruscel
membran
fusion
gp
bind
receptor
gp
cleav
signific
portion
lost
remain
peptid
undergo
geometr
rearrang
initi
fusion
antibodi
simultan
bind
epitop
interf
seri
structur
arrang
requir
viruscel
membran
fusion
e
antigp
mab
may
also
bind
gp
molecul
expos
surfac
infect
cell
mark
host
immun
respons
attack
mechan
includ
antibodydepend
cellmedi
cytotox
adcc
f
bind
sgp
conceiv
decreas
number
mab
unit
avail
interfer
transmembran
cleav
gp
comparison
differ
platform
produc
antiebov
immun
therapeut
transient
express
tobacco
leav
easili
scalabl
solut
cho
cell
cultur
exhibit
limit
capac
cost
altern
product
mab
fragment
bacteri
cultur
could
costeffect
altern
face
ebov
epidem
amino
acid
sequenc
gp
epitop
target
differ
antiebola
mab
conserv
amino
acid
among
differ
zair
ebov
strain
mark
black
amino
acid
posit
differ
among
zair
ebov
strain
indic
gray
et
al
page
tabl
genet
sequenc
variabl
heavi
vh
light
vl
chain
antibodi
includ
mab
cocktail
proven
protect
nonhuman
primat
ebov
lethal
challeng
experi
vh
vl
sequenc
mab
protect
guinea
pig
humanprim
also
includ
